can you take nolva and letro together?
Printable View
can you take nolva and letro together?
bump
yes i do with great results. have for quite sometime now...
how much of each do u take during cycle?
i'm taking letro right now.. 2.5mg. I'm getting gyno symptoms, so i'm going to get nolva.
what is your cycle how often do you take letro ed or eod at 2.5mg. Letro is supposed to work alot better for gyno then nolva.
Thats what i thought.. how long does it take to start working.. my nipples are getting puffier and are starting to hurt... i can also squeeze water out of the left one.. actually its only the left..
of course, an agonist-antagonist plus a competitive inhibitor.
even better: evista or fareston plus aromasin (suicide inhibitor).
I don't know what that meansQuote:
Originally Posted by oswaldosalcedo
estrogen attach at estrogen receptors,nolva it,evista and fareston even more,Quote:
Originally Posted by jaym_100
it occupies the places availables at receptors, that way there is no unoccupied receptors.
AGONIST
Fitting a sigmoidal (logistic) equation to a dose-response curve to determine EC50 (and perhaps slope factor) doesn't tell you everything you want to know about an agonist. The EC50 reflects both the ability of the drug to bind to its receptor (the agonist's affinity) and the ability of the drug to cause a response once it is bound (the agonist's efficacy). Thus, the EC50 you observe could have different causes. The agonist could bind with very high affinity, but have low efficacy once bound. Or it could bind weakly with low affinity, but have very high efficacy. Two very different drugs could have the same EC50s and maximal responses (in the same tissue). One drug could have high affinity and low efficacy, while the other has low affinity and high efficacy. Since efficacy reflects properties of both agonist and tissue, a single drug acting on one kind of receptor could have different EC50 values in different tissues.
------------------------------------------------
inhibitors
inhibitors binds at the enzimes (aromatase)
competitive inhibitors just bind it and inactivate it (transitorily).
suicide inhibitors destroy it.(inactivates forever)
Thanks for clearing that up
nolva and letro work well. letro will hurt your cholesterol while nolva will help your profile. good way to keep the water off and combat gyno.
Ann Oncol. 2005 May;16(5):707-15. Epub 2005 Apr 7.
The influence of letrozole on serum lipid concentrations
Wasan KM, Goss PE, Pritchard PH, Shepherd L, Palmer MJ, Liu S, Tu D, Ingle JN, Heath M, Deangelis D, Perez EA.
Division of Pharmaceutics and Biopharmaceutics, Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada. [email protected]
BACKGROUND: The purpose of this study was to evaluate changes in serum lipid parameters {cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides and lipoprotein(a) [Lp(a)]}, in postmenopausal women receiving letrozole or placebo after adjuvant tamoxifen for early stage breast cancer (NCIC CTG MA.17L). PATIENTS AND METHODS: MA.17L is a substudy of MA.17, a randomized, double-blind, placebo-controlled trial of letrozole 2.5 mg taken daily for 5 years in postmenopausal women with primary breast cancer completing approximately 5 years of prior adjuvant tamoxifen. Patients consenting to participate in this companion study had blood drawn and lipid parameters (total cholesterol, HDL cholesterol, LDL cholesterol, Lp(a), triglycerides) evaluated at baseline, 6 months, 12 months and yearly thereafter until completion of protocol therapy. It was required that women be non-hyperlipidemic and not taking lipid-lowering drugs at time of entry on this trial. RESULTS: Three hundred and forty seven women were enrolled in the study. The letrozole and the placebo groups demonstrated marginally significant differences in the percentage change from baseline in HDL cholesterol at 6 months (P=0.049), in LDL cholesterol at 12 months (P=0.033) and triglycerides at 24 months (P=0.036). All comparisons of lipid parameters at other time points were not significantly different between the two treatment groups. No statistically significant differences in the number of patients exceeding the thresholds defined for the lipid parameters were found between the two treatment groups. CONCLUSIONS: The MA.17 trial demonstrated a significant improvement in disease-free survival with the use of letrozole as extended adjuvant therapy post tamoxifen. Results from this study suggests that letrozole does not significantly alter serum cholesterol, HDL cholesterol, LDL cholesterol, triglycerides or Lp(a) in non-hyperlidiemic postmenopausal women with primary breast cancer treated up to 36 months following at least 5 years of adjuvant tamoxifen therapy. These findings further support the tolerability of extended adjuvant letrozole in postmenopausal women following standard tamoxifen therapy."
Thx for info!! :wg:Quote:
Originally Posted by oswaldosalcedo
at your service !
quit squezeing them:rolleyes:Quote:
Originally Posted by jaym_100
Nice post oswaldosalcedo
Hey Zomzom, are ya tracking down my posts? :lol:........thought soQuote:
Originally Posted by zomzom